Thanks to the development of antiretroviral agents to control HIV replication, HIV infection has turned from a fatal disease into a treatable chronic infection. The present work collects the opinions of several experts on the efficacy and safety of recently approved second generation of integrase inhibitors and, in particular, on the role of this new class of drugs in antiretroviral therapy. The availability of new therapeutic options represents an opportunity to ameliorate the efficacy of cART in controlling HIV replication also within viral reservoirs. The personalization of the treatment driven mainly by the management of comorbidities, HIV-HCV co-infections and aging, will be easier with antiretroviral drugs without drug-drug interactions and with a better toxicity and tolerability profile. Future assessment of economic impact for the introduction of new innovative drugs in the field of antiretroviral therapy will likely need some degree of adjustment of the evaluation criteria of costs and benefit which are currently based almost exclusively on morbidity and mortality.

An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project / Andreoni, Massimo; Marcotullio, Simone; Puro, Vincenzo; De Carli, Gabriella; Tambussi, Giuseppe; Nozza, Silvia; Gori, Andrea; Rusconi, Stefano; Santoro, Maria Mercedes; Clementi, Massimo; Perno, Carlo Federico; d’Arminio Monforte, Antonella; Maggiolo, Franco; Castagna, Antonella; De Luca, Andrea; Galli, Massimo; Giacomelli, Andrea; Borderi, Marco; Guaraldi, Giovanni; Calcagno, Andrea; Di Perri, Giovanni; Bonora, Stefano; Mussini, Cristina; Di Biagio, Antonio; Puoti, Massimo; Bruno, Raffaele; Zuccaro, Valentina; Antinori, Andrea; Cinque, Paola; Croce, Davide; Restelli, Umberto; Rizzardini, Giuliano; Lazzarin, Adriano. - In: NEW MICROBIOLOGICA. - ISSN 1121-7138. - 38:4(2015), pp. 443-490.

An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project

GUARALDI, Giovanni;MUSSINI, Cristina;
2015

Abstract

Thanks to the development of antiretroviral agents to control HIV replication, HIV infection has turned from a fatal disease into a treatable chronic infection. The present work collects the opinions of several experts on the efficacy and safety of recently approved second generation of integrase inhibitors and, in particular, on the role of this new class of drugs in antiretroviral therapy. The availability of new therapeutic options represents an opportunity to ameliorate the efficacy of cART in controlling HIV replication also within viral reservoirs. The personalization of the treatment driven mainly by the management of comorbidities, HIV-HCV co-infections and aging, will be easier with antiretroviral drugs without drug-drug interactions and with a better toxicity and tolerability profile. Future assessment of economic impact for the introduction of new innovative drugs in the field of antiretroviral therapy will likely need some degree of adjustment of the evaluation criteria of costs and benefit which are currently based almost exclusively on morbidity and mortality.
38
4
443
490
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project / Andreoni, Massimo; Marcotullio, Simone; Puro, Vincenzo; De Carli, Gabriella; Tambussi, Giuseppe; Nozza, Silvia; Gori, Andrea; Rusconi, Stefano; Santoro, Maria Mercedes; Clementi, Massimo; Perno, Carlo Federico; d’Arminio Monforte, Antonella; Maggiolo, Franco; Castagna, Antonella; De Luca, Andrea; Galli, Massimo; Giacomelli, Andrea; Borderi, Marco; Guaraldi, Giovanni; Calcagno, Andrea; Di Perri, Giovanni; Bonora, Stefano; Mussini, Cristina; Di Biagio, Antonio; Puoti, Massimo; Bruno, Raffaele; Zuccaro, Valentina; Antinori, Andrea; Cinque, Paola; Croce, Davide; Restelli, Umberto; Rizzardini, Giuliano; Lazzarin, Adriano. - In: NEW MICROBIOLOGICA. - ISSN 1121-7138. - 38:4(2015), pp. 443-490.
Andreoni, Massimo; Marcotullio, Simone; Puro, Vincenzo; De Carli, Gabriella; Tambussi, Giuseppe; Nozza, Silvia; Gori, Andrea; Rusconi, Stefano; Santoro, Maria Mercedes; Clementi, Massimo; Perno, Carlo Federico; d’Arminio Monforte, Antonella; Maggiolo, Franco; Castagna, Antonella; De Luca, Andrea; Galli, Massimo; Giacomelli, Andrea; Borderi, Marco; Guaraldi, Giovanni; Calcagno, Andrea; Di Perri, Giovanni; Bonora, Stefano; Mussini, Cristina; Di Biagio, Antonio; Puoti, Massimo; Bruno, Raffaele; Zuccaro, Valentina; Antinori, Andrea; Cinque, Paola; Croce, Davide; Restelli, Umberto; Rizzardini, Giuliano; Lazzarin, Adriano
File in questo prodotto:
File Dimensione Formato  
443.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 812.55 kB
Formato Adobe PDF
812.55 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1102431
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 10
social impact